nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—Cytochrome P450 2D6 Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.208	0.358	CiPCiCtD
Pazopanib—Cytochrome P450 3A4 Inhibitors—Amprenavir—acquired immunodeficiency syndrome	0.154	0.265	CiPCiCtD
Pazopanib—Cytochrome P450 3A4 Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.11	0.189	CiPCiCtD
Pazopanib—Cytochrome P450 3A4 Inhibitors—Efavirenz—acquired immunodeficiency syndrome	0.11	0.189	CiPCiCtD
Pazopanib—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.032	0.125	CbGbCtD
Pazopanib—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.0123	0.0482	CbGbCtD
Pazopanib—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.012	0.0468	CbGbCtD
Pazopanib—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0423	CbGbCtD
Pazopanib—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0423	CbGbCtD
Pazopanib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0095	0.0371	CbGbCtD
Pazopanib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.00859	0.0336	CbGbCtD
Pazopanib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.00859	0.0336	CbGbCtD
Pazopanib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.00823	0.0322	CbGbCtD
Pazopanib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00637	0.0249	CbGbCtD
Pazopanib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.00604	0.0236	CbGbCtD
Pazopanib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.00604	0.0236	CbGbCtD
Pazopanib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0055	0.0215	CbGbCtD
Pazopanib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.00517	0.0202	CbGbCtD
Pazopanib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.00517	0.0202	CbGbCtD
Pazopanib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00467	0.0183	CbGbCtD
Pazopanib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00457	0.0179	CbGbCtD
Pazopanib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00457	0.0179	CbGbCtD
Pazopanib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00453	0.0177	CbGbCtD
Pazopanib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00452	0.0177	CbGbCtD
Pazopanib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00439	0.0172	CbGbCtD
Pazopanib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00426	0.0167	CbGbCtD
Pazopanib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00426	0.0167	CbGbCtD
Pazopanib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00409	0.016	CbGbCtD
Pazopanib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00392	0.0153	CbGbCtD
Pazopanib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00385	0.0151	CbGbCtD
Pazopanib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00385	0.0151	CbGbCtD
Pazopanib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00354	0.0139	CbGbCtD
Pazopanib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00353	0.0138	CbGbCtD
Pazopanib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00342	0.0134	CbGbCtD
Pazopanib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00332	0.013	CbGbCtD
Pazopanib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00323	0.0126	CbGbCtD
Pazopanib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0031	0.0121	CbGbCtD
Pazopanib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0031	0.0121	CbGbCtD
Pazopanib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00297	0.0116	CbGbCtD
Pazopanib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00292	0.0114	CbGbCtD
Pazopanib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00292	0.0114	CbGbCtD
Pazopanib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00288	0.0113	CbGbCtD
Pazopanib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00271	0.0106	CbGbCtD
Pazopanib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00271	0.0106	CbGbCtD
Pazopanib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00245	0.00958	CbGbCtD
Pazopanib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00245	0.00958	CbGbCtD
Pazopanib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0023	0.00898	CbGbCtD
Pazopanib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00211	0.00827	CbGbCtD
Pazopanib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00205	0.00802	CbGbCtD
Pazopanib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00186	0.00726	CbGbCtD
Pazopanib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00186	0.00726	CbGbCtD
Pazopanib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00178	0.00696	CbGbCtD
Pazopanib—PI4KB—bone marrow—acquired immunodeficiency syndrome	0.000196	0.00376	CbGeAlD
Pazopanib—TAOK3—retina—acquired immunodeficiency syndrome	0.000195	0.00376	CbGeAlD
Pazopanib—PI4KB—spinal cord—acquired immunodeficiency syndrome	0.000195	0.00375	CbGeAlD
Pazopanib—LIMK2—spinal cord—acquired immunodeficiency syndrome	0.000191	0.00368	CbGeAlD
Pazopanib—ITK—lymph node—acquired immunodeficiency syndrome	0.000191	0.00368	CbGeAlD
Pazopanib—STK36—vagina—acquired immunodeficiency syndrome	0.00019	0.00366	CbGeAlD
Pazopanib—FLT4—lymphoid tissue—acquired immunodeficiency syndrome	0.000189	0.00365	CbGeAlD
Pazopanib—STK16—nervous system—acquired immunodeficiency syndrome	0.000188	0.00363	CbGeAlD
Pazopanib—PI4KB—vagina—acquired immunodeficiency syndrome	0.000187	0.00361	CbGeAlD
Pazopanib—LYN—nervous system—acquired immunodeficiency syndrome	0.000186	0.00359	CbGeAlD
Pazopanib—FGFR3—nervous system—acquired immunodeficiency syndrome	0.000185	0.00357	CbGeAlD
Pazopanib—RIOK2—nervous system—acquired immunodeficiency syndrome	0.000185	0.00357	CbGeAlD
Pazopanib—LIMK2—vagina—acquired immunodeficiency syndrome	0.000184	0.00354	CbGeAlD
Pazopanib—MAP3K19—nervous system—acquired immunodeficiency syndrome	0.000184	0.00353	CbGeAlD
Pazopanib—BMPR1B—nervous system—acquired immunodeficiency syndrome	0.000184	0.00353	CbGeAlD
Pazopanib—STK16—central nervous system—acquired immunodeficiency syndrome	0.000181	0.00349	CbGeAlD
Pazopanib—STK36—lung—acquired immunodeficiency syndrome	0.00018	0.00346	CbGeAlD
Pazopanib—TAOK1—brain—acquired immunodeficiency syndrome	0.00018	0.00346	CbGeAlD
Pazopanib—EPHB6—skin of body—acquired immunodeficiency syndrome	0.00018	0.00346	CbGeAlD
Pazopanib—LYN—central nervous system—acquired immunodeficiency syndrome	0.000179	0.00346	CbGeAlD
Pazopanib—MAP3K2—lymphoid tissue—acquired immunodeficiency syndrome	0.000179	0.00344	CbGeAlD
Pazopanib—RIOK2—central nervous system—acquired immunodeficiency syndrome	0.000179	0.00344	CbGeAlD
Pazopanib—FGFR3—central nervous system—acquired immunodeficiency syndrome	0.000179	0.00344	CbGeAlD
Pazopanib—FLT4—blood—acquired immunodeficiency syndrome	0.000178	0.00343	CbGeAlD
Pazopanib—PIP4K2C—blood—acquired immunodeficiency syndrome	0.000177	0.00341	CbGeAlD
Pazopanib—PI4KB—lung—acquired immunodeficiency syndrome	0.000177	0.00341	CbGeAlD
Pazopanib—BMPR1B—central nervous system—acquired immunodeficiency syndrome	0.000177	0.0034	CbGeAlD
Pazopanib—MAP3K19—central nervous system—acquired immunodeficiency syndrome	0.000177	0.0034	CbGeAlD
Pazopanib—KDR—retina—acquired immunodeficiency syndrome	0.000175	0.00337	CbGeAlD
Pazopanib—LIMK2—lung—acquired immunodeficiency syndrome	0.000174	0.00335	CbGeAlD
Pazopanib—TAOK1—lymph node—acquired immunodeficiency syndrome	0.000174	0.00335	CbGeAlD
Pazopanib—FLT4—bone marrow—acquired immunodeficiency syndrome	0.000172	0.00332	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—acquired immunodeficiency syndrome	0.000172	0.0033	CbGeAlD
Pazopanib—PIP4K2C—spinal cord—acquired immunodeficiency syndrome	0.000171	0.00329	CbGeAlD
Pazopanib—FGFR1—spinal cord—acquired immunodeficiency syndrome	0.000169	0.00326	CbGeAlD
Pazopanib—SH2B3—brain—acquired immunodeficiency syndrome	0.000169	0.00326	CbGeAlD
Pazopanib—FGF1—lymphoid tissue—acquired immunodeficiency syndrome	0.000168	0.00324	CbGeAlD
Pazopanib—MAP3K2—blood—acquired immunodeficiency syndrome	0.000168	0.00324	CbGeAlD
Pazopanib—AURKC—brain—acquired immunodeficiency syndrome	0.000167	0.00321	CbGeAlD
Pazopanib—STK36—nervous system—acquired immunodeficiency syndrome	0.000167	0.00321	CbGeAlD
Pazopanib—FGF1—digestive system—acquired immunodeficiency syndrome	0.000166	0.0032	CbGeAlD
Pazopanib—PIP4K2C—vagina—acquired immunodeficiency syndrome	0.000164	0.00316	CbGeAlD
Pazopanib—PI4KB—nervous system—acquired immunodeficiency syndrome	0.000164	0.00316	CbGeAlD
Pazopanib—SH2B3—lymph node—acquired immunodeficiency syndrome	0.000164	0.00315	CbGeAlD
Pazopanib—FGFR1—vagina—acquired immunodeficiency syndrome	0.000163	0.00314	CbGeAlD
Pazopanib—MAP3K2—bone marrow—acquired immunodeficiency syndrome	0.000163	0.00313	CbGeAlD
Pazopanib—AURKC—lymph node—acquired immunodeficiency syndrome	0.000161	0.0031	CbGeAlD
Pazopanib—LIMK2—nervous system—acquired immunodeficiency syndrome	0.000161	0.0031	CbGeAlD
Pazopanib—STK36—central nervous system—acquired immunodeficiency syndrome	0.00016	0.00309	CbGeAlD
Pazopanib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00016	0.00308	CbGeAlD
Pazopanib—FGF1—blood—acquired immunodeficiency syndrome	0.000158	0.00305	CbGeAlD
Pazopanib—PI4KB—central nervous system—acquired immunodeficiency syndrome	0.000158	0.00304	CbGeAlD
Pazopanib—LCK—blood—acquired immunodeficiency syndrome	0.000157	0.00303	CbGeAlD
Pazopanib—FGFR2—digestive system—acquired immunodeficiency syndrome	0.000157	0.00302	CbGeAlD
Pazopanib—FLT4—lung—acquired immunodeficiency syndrome	0.000156	0.00301	CbGeAlD
Pazopanib—PIP4K2C—lung—acquired immunodeficiency syndrome	0.000155	0.00299	CbGeAlD
Pazopanib—LIMK2—central nervous system—acquired immunodeficiency syndrome	0.000155	0.00299	CbGeAlD
Pazopanib—FGFR1—lung—acquired immunodeficiency syndrome	0.000154	0.00297	CbGeAlD
Pazopanib—FGF1—spinal cord—acquired immunodeficiency syndrome	0.000153	0.00294	CbGeAlD
Pazopanib—PLK4—brain—acquired immunodeficiency syndrome	0.000152	0.00294	CbGeAlD
Pazopanib—LCK—bone marrow—acquired immunodeficiency syndrome	0.000152	0.00293	CbGeAlD
Pazopanib—CSF1R—skin of body—acquired immunodeficiency syndrome	0.00015	0.00289	CbGeAlD
Pazopanib—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00015	0.00288	CbGeAlD
Pazopanib—FGFR2—blood—acquired immunodeficiency syndrome	0.00015	0.00288	CbGeAlD
Pazopanib—MAP3K2—lung—acquired immunodeficiency syndrome	0.000147	0.00284	CbGeAlD
Pazopanib—PLK4—lymph node—acquired immunodeficiency syndrome	0.000147	0.00284	CbGeAlD
Pazopanib—FLT1—lymphoid tissue—acquired immunodeficiency syndrome	0.000147	0.00284	CbGeAlD
Pazopanib—LCK—vagina—acquired immunodeficiency syndrome	0.000146	0.00281	CbGeAlD
Pazopanib—FLT1—digestive system—acquired immunodeficiency syndrome	0.000145	0.0028	CbGeAlD
Pazopanib—FGFR2—spinal cord—acquired immunodeficiency syndrome	0.000144	0.00277	CbGeAlD
Pazopanib—STK16—brain—acquired immunodeficiency syndrome	0.000144	0.00277	CbGeAlD
Pazopanib—PIP4K2C—nervous system—acquired immunodeficiency syndrome	0.000144	0.00277	CbGeAlD
Pazopanib—LYN—brain—acquired immunodeficiency syndrome	0.000142	0.00274	CbGeAlD
Pazopanib—RIOK2—brain—acquired immunodeficiency syndrome	0.000142	0.00273	CbGeAlD
Pazopanib—FGFR3—brain—acquired immunodeficiency syndrome	0.000142	0.00273	CbGeAlD
Pazopanib—MAP3K19—brain—acquired immunodeficiency syndrome	0.00014	0.0027	CbGeAlD
Pazopanib—BMPR1B—brain—acquired immunodeficiency syndrome	0.00014	0.0027	CbGeAlD
Pazopanib—STK10—lymphoid tissue—acquired immunodeficiency syndrome	0.000139	0.00268	CbGeAlD
Pazopanib—STK16—lymph node—acquired immunodeficiency syndrome	0.000139	0.00268	CbGeAlD
Pazopanib—TAOK3—lymphoid tissue—acquired immunodeficiency syndrome	0.000139	0.00267	CbGeAlD
Pazopanib—FGF1—lung—acquired immunodeficiency syndrome	0.000139	0.00267	CbGeAlD
Pazopanib—FLT1—blood—acquired immunodeficiency syndrome	0.000139	0.00267	CbGeAlD
Pazopanib—PIP4K2C—central nervous system—acquired immunodeficiency syndrome	0.000139	0.00267	CbGeAlD
Pazopanib—PDGFRA—lymphoid tissue—acquired immunodeficiency syndrome	0.000138	0.00266	CbGeAlD
Pazopanib—LCK—lung—acquired immunodeficiency syndrome	0.000138	0.00266	CbGeAlD
Pazopanib—STK10—digestive system—acquired immunodeficiency syndrome	0.000138	0.00265	CbGeAlD
Pazopanib—TAOK3—digestive system—acquired immunodeficiency syndrome	0.000137	0.00264	CbGeAlD
Pazopanib—EPHB6—blood—acquired immunodeficiency syndrome	0.000137	0.00264	CbGeAlD
Pazopanib—RIOK2—lymph node—acquired immunodeficiency syndrome	0.000137	0.00264	CbGeAlD
Pazopanib—MAP3K2—nervous system—acquired immunodeficiency syndrome	0.000136	0.00263	CbGeAlD
Pazopanib—PDGFRA—digestive system—acquired immunodeficiency syndrome	0.000136	0.00262	CbGeAlD
Pazopanib—KIT—skin of body—acquired immunodeficiency syndrome	0.000136	0.00262	CbGeAlD
Pazopanib—BMPR1B—lymph node—acquired immunodeficiency syndrome	0.000136	0.00261	CbGeAlD
Pazopanib—FLT1—spinal cord—acquired immunodeficiency syndrome	0.000134	0.00257	CbGeAlD
Pazopanib—PDGFRB—skin of body—acquired immunodeficiency syndrome	0.000133	0.00256	CbGeAlD
Pazopanib—EPHB6—spinal cord—acquired immunodeficiency syndrome	0.000132	0.00254	CbGeAlD
Pazopanib—MAP3K2—central nervous system—acquired immunodeficiency syndrome	0.000131	0.00253	CbGeAlD
Pazopanib—STK10—blood—acquired immunodeficiency syndrome	0.000131	0.00253	CbGeAlD
Pazopanib—FGFR2—lung—acquired immunodeficiency syndrome	0.000131	0.00252	CbGeAlD
Pazopanib—TAOK3—blood—acquired immunodeficiency syndrome	0.000131	0.00252	CbGeAlD
Pazopanib—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.00013	0.0025	CbGeAlD
Pazopanib—PDGFRA—blood—acquired immunodeficiency syndrome	0.00013	0.0025	CbGeAlD
Pazopanib—FGF1—nervous system—acquired immunodeficiency syndrome	0.000129	0.00247	CbGeAlD
Pazopanib—FLT1—vagina—acquired immunodeficiency syndrome	0.000128	0.00247	CbGeAlD
Pazopanib—STK36—brain—acquired immunodeficiency syndrome	0.000127	0.00245	CbGeAlD
Pazopanib—EPHB6—vagina—acquired immunodeficiency syndrome	0.000127	0.00245	CbGeAlD
Pazopanib—STK10—bone marrow—acquired immunodeficiency syndrome	0.000127	0.00244	CbGeAlD
Pazopanib—TAOK3—bone marrow—acquired immunodeficiency syndrome	0.000126	0.00243	CbGeAlD
Pazopanib—TAOK3—spinal cord—acquired immunodeficiency syndrome	0.000126	0.00242	CbGeAlD
Pazopanib—PI4KB—brain—acquired immunodeficiency syndrome	0.000125	0.00241	CbGeAlD
Pazopanib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.000125	0.00241	CbGeAlD
Pazopanib—KDR—lymphoid tissue—acquired immunodeficiency syndrome	0.000125	0.0024	CbGeAlD
Pazopanib—UGT1A1—blood—acquired immunodeficiency syndrome	0.000124	0.00239	CbGeAlD
Pazopanib—FGF1—central nervous system—acquired immunodeficiency syndrome	0.000124	0.00238	CbGeAlD
Pazopanib—LIMK2—brain—acquired immunodeficiency syndrome	0.000123	0.00237	CbGeAlD
Pazopanib—STK36—lymph node—acquired immunodeficiency syndrome	0.000123	0.00237	CbGeAlD
Pazopanib—KDR—digestive system—acquired immunodeficiency syndrome	0.000123	0.00237	CbGeAlD
Pazopanib—STK10—vagina—acquired immunodeficiency syndrome	0.000122	0.00234	CbGeAlD
Pazopanib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	0.000122	0.00234	CbGeAlD
Pazopanib—FLT1—lung—acquired immunodeficiency syndrome	0.000122	0.00234	CbGeAlD
Pazopanib—FGFR2—nervous system—acquired immunodeficiency syndrome	0.000121	0.00234	CbGeAlD
Pazopanib—TAOK3—vagina—acquired immunodeficiency syndrome	0.000121	0.00233	CbGeAlD
Pazopanib—PI4KB—lymph node—acquired immunodeficiency syndrome	0.000121	0.00233	CbGeAlD
Pazopanib—PDGFRA—vagina—acquired immunodeficiency syndrome	0.00012	0.00232	CbGeAlD
Pazopanib—EPHB6—lung—acquired immunodeficiency syndrome	0.00012	0.00231	CbGeAlD
Pazopanib—CSF1R—digestive system—acquired immunodeficiency syndrome	0.00012	0.00231	CbGeAlD
Pazopanib—LIMK2—lymph node—acquired immunodeficiency syndrome	0.000119	0.00229	CbGeAlD
Pazopanib—KDR—blood—acquired immunodeficiency syndrome	0.000117	0.00226	CbGeAlD
Pazopanib—MAP2K5—blood—acquired immunodeficiency syndrome	0.000117	0.00226	CbGeAlD
Pazopanib—FGFR2—central nervous system—acquired immunodeficiency syndrome	0.000117	0.00225	CbGeAlD
Pazopanib—STK10—lung—acquired immunodeficiency syndrome	0.000115	0.00221	CbGeAlD
Pazopanib—TAOK3—lung—acquired immunodeficiency syndrome	0.000115	0.00221	CbGeAlD
Pazopanib—CSF1R—blood—acquired immunodeficiency syndrome	0.000114	0.0022	CbGeAlD
Pazopanib—PDGFRA—lung—acquired immunodeficiency syndrome	0.000114	0.00219	CbGeAlD
Pazopanib—KDR—bone marrow—acquired immunodeficiency syndrome	0.000113	0.00218	CbGeAlD
Pazopanib—KDR—spinal cord—acquired immunodeficiency syndrome	0.000113	0.00217	CbGeAlD
Pazopanib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	0.000113	0.00217	CbGeAlD
Pazopanib—FLT1—nervous system—acquired immunodeficiency syndrome	0.000113	0.00217	CbGeAlD
Pazopanib—EPHB6—nervous system—acquired immunodeficiency syndrome	0.000111	0.00214	CbGeAlD
Pazopanib—CSF1R—bone marrow—acquired immunodeficiency syndrome	0.000111	0.00213	CbGeAlD
Pazopanib—FLT4—brain—acquired immunodeficiency syndrome	0.000111	0.00213	CbGeAlD
Pazopanib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	0.00011	0.00212	CbGeAlD
Pazopanib—CSF1R—spinal cord—acquired immunodeficiency syndrome	0.00011	0.00212	CbGeAlD
Pazopanib—PIP4K2C—brain—acquired immunodeficiency syndrome	0.00011	0.00212	CbGeAlD
Pazopanib—FGFR1—brain—acquired immunodeficiency syndrome	0.000109	0.0021	CbGeAlD
Pazopanib—KIT—digestive system—acquired immunodeficiency syndrome	0.000109	0.0021	CbGeAlD
Pazopanib—KDR—vagina—acquired immunodeficiency syndrome	0.000109	0.00209	CbGeAlD
Pazopanib—MAP2K5—vagina—acquired immunodeficiency syndrome	0.000109	0.00209	CbGeAlD
Pazopanib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000108	0.00209	CbGeAlD
Pazopanib—FLT1—central nervous system—acquired immunodeficiency syndrome	0.000108	0.00209	CbGeAlD
Pazopanib—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.000108	0.00208	CbGeAlD
Pazopanib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	0.000108	0.00207	CbGeAlD
Pazopanib—EPHB6—central nervous system—acquired immunodeficiency syndrome	0.000107	0.00206	CbGeAlD
Pazopanib—FLT4—lymph node—acquired immunodeficiency syndrome	0.000107	0.00206	CbGeAlD
Pazopanib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000107	0.00205	CbGeAlD
Pazopanib—STK10—nervous system—acquired immunodeficiency syndrome	0.000107	0.00205	CbGeAlD
Pazopanib—PDGFRB—digestive system—acquired immunodeficiency syndrome	0.000106	0.00205	CbGeAlD
Pazopanib—PIP4K2C—lymph node—acquired immunodeficiency syndrome	0.000106	0.00205	CbGeAlD
Pazopanib—TAOK3—nervous system—acquired immunodeficiency syndrome	0.000106	0.00204	CbGeAlD
Pazopanib—CSF1R—vagina—acquired immunodeficiency syndrome	0.000106	0.00204	CbGeAlD
Pazopanib—FGFR1—lymph node—acquired immunodeficiency syndrome	0.000105	0.00203	CbGeAlD
Pazopanib—PDGFRA—nervous system—acquired immunodeficiency syndrome	0.000105	0.00203	CbGeAlD
Pazopanib—MAP3K2—brain—acquired immunodeficiency syndrome	0.000104	0.00201	CbGeAlD
Pazopanib—KIT—blood—acquired immunodeficiency syndrome	0.000104	0.002	CbGeAlD
Pazopanib—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000103	0.00199	CbGeAlD
Pazopanib—KDR—lung—acquired immunodeficiency syndrome	0.000103	0.00198	CbGeAlD
Pazopanib—MAP2K5—lung—acquired immunodeficiency syndrome	0.000103	0.00198	CbGeAlD
Pazopanib—STK10—central nervous system—acquired immunodeficiency syndrome	0.000103	0.00197	CbGeAlD
Pazopanib—TAOK3—central nervous system—acquired immunodeficiency syndrome	0.000102	0.00197	CbGeAlD
Pazopanib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	0.000102	0.00195	CbGeAlD
Pazopanib—PDGFRB—blood—acquired immunodeficiency syndrome	0.000101	0.00195	CbGeAlD
Pazopanib—MAP3K2—lymph node—acquired immunodeficiency syndrome	0.000101	0.00194	CbGeAlD
Pazopanib—KIT—bone marrow—acquired immunodeficiency syndrome	0.0001	0.00193	CbGeAlD
Pazopanib—CSF1R—lung—acquired immunodeficiency syndrome	0.0001	0.00193	CbGeAlD
Pazopanib—KIT—spinal cord—acquired immunodeficiency syndrome	0.0001	0.00193	CbGeAlD
Pazopanib—FGF1—brain—acquired immunodeficiency syndrome	9.83e-05	0.00189	CbGeAlD
Pazopanib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	9.81e-05	0.00189	CbGeAlD
Pazopanib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	9.77e-05	0.00188	CbGeAlD
Pazopanib—KIT—vagina—acquired immunodeficiency syndrome	9.63e-05	0.00185	CbGeAlD
Pazopanib—KDR—nervous system—acquired immunodeficiency syndrome	9.51e-05	0.00183	CbGeAlD
Pazopanib—MAP2K5—nervous system—acquired immunodeficiency syndrome	9.51e-05	0.00183	CbGeAlD
Pazopanib—FGF1—lymph node—acquired immunodeficiency syndrome	9.49e-05	0.00183	CbGeAlD
Pazopanib—LCK—lymph node—acquired immunodeficiency syndrome	9.44e-05	0.00182	CbGeAlD
Pazopanib—PDGFRB—vagina—acquired immunodeficiency syndrome	9.4e-05	0.00181	CbGeAlD
Pazopanib—CSF1R—nervous system—acquired immunodeficiency syndrome	9.28e-05	0.00179	CbGeAlD
Pazopanib—FGFR2—brain—acquired immunodeficiency syndrome	9.28e-05	0.00179	CbGeAlD
Pazopanib—KDR—central nervous system—acquired immunodeficiency syndrome	9.16e-05	0.00176	CbGeAlD
Pazopanib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	9.16e-05	0.00176	CbGeAlD
Pazopanib—KIT—lung—acquired immunodeficiency syndrome	9.1e-05	0.00175	CbGeAlD
Pazopanib—CSF1R—central nervous system—acquired immunodeficiency syndrome	8.94e-05	0.00172	CbGeAlD
Pazopanib—PDGFRB—lung—acquired immunodeficiency syndrome	8.89e-05	0.00171	CbGeAlD
Pazopanib—FLT1—brain—acquired immunodeficiency syndrome	8.6e-05	0.00166	CbGeAlD
Pazopanib—EPHB6—brain—acquired immunodeficiency syndrome	8.5e-05	0.00164	CbGeAlD
Pazopanib—KIT—nervous system—acquired immunodeficiency syndrome	8.43e-05	0.00162	CbGeAlD
Pazopanib—FLT1—lymph node—acquired immunodeficiency syndrome	8.31e-05	0.0016	CbGeAlD
Pazopanib—PDGFRB—nervous system—acquired immunodeficiency syndrome	8.23e-05	0.00159	CbGeAlD
Pazopanib—EPHB6—lymph node—acquired immunodeficiency syndrome	8.21e-05	0.00158	CbGeAlD
Pazopanib—STK10—brain—acquired immunodeficiency syndrome	8.14e-05	0.00157	CbGeAlD
Pazopanib—KIT—central nervous system—acquired immunodeficiency syndrome	8.12e-05	0.00156	CbGeAlD
Pazopanib—TAOK3—brain—acquired immunodeficiency syndrome	8.11e-05	0.00156	CbGeAlD
Pazopanib—PDGFRA—brain—acquired immunodeficiency syndrome	8.06e-05	0.00155	CbGeAlD
Pazopanib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	7.93e-05	0.00153	CbGeAlD
Pazopanib—STK10—lymph node—acquired immunodeficiency syndrome	7.87e-05	0.00151	CbGeAlD
Pazopanib—TAOK3—lymph node—acquired immunodeficiency syndrome	7.84e-05	0.00151	CbGeAlD
Pazopanib—PDGFRA—lymph node—acquired immunodeficiency syndrome	7.79e-05	0.0015	CbGeAlD
Pazopanib—ABCB1—blood plasma—acquired immunodeficiency syndrome	7.67e-05	0.00148	CbGeAlD
Pazopanib—KDR—brain—acquired immunodeficiency syndrome	7.27e-05	0.0014	CbGeAlD
Pazopanib—MAP2K5—brain—acquired immunodeficiency syndrome	7.27e-05	0.0014	CbGeAlD
Pazopanib—CSF1R—brain—acquired immunodeficiency syndrome	7.1e-05	0.00137	CbGeAlD
Pazopanib—KDR—lymph node—acquired immunodeficiency syndrome	7.03e-05	0.00135	CbGeAlD
Pazopanib—MAP2K5—lymph node—acquired immunodeficiency syndrome	7.03e-05	0.00135	CbGeAlD
Pazopanib—CSF1R—lymph node—acquired immunodeficiency syndrome	6.86e-05	0.00132	CbGeAlD
Pazopanib—KIT—brain—acquired immunodeficiency syndrome	6.44e-05	0.00124	CbGeAlD
Pazopanib—PDGFRB—brain—acquired immunodeficiency syndrome	6.29e-05	0.00121	CbGeAlD
Pazopanib—KIT—lymph node—acquired immunodeficiency syndrome	6.23e-05	0.0012	CbGeAlD
Pazopanib—PDGFRB—lymph node—acquired immunodeficiency syndrome	6.08e-05	0.00117	CbGeAlD
Pazopanib—CYP2C8—blood—acquired immunodeficiency syndrome	5.86e-05	0.00113	CbGeAlD
Pazopanib—CYP1A2—digestive system—acquired immunodeficiency syndrome	5.76e-05	0.00111	CbGeAlD
Pazopanib—ABCG2—blood—acquired immunodeficiency syndrome	5.7e-05	0.0011	CbGeAlD
Pazopanib—ABCG2—bone marrow—acquired immunodeficiency syndrome	5.52e-05	0.00106	CbGeAlD
Pazopanib—ABCG2—spinal cord—acquired immunodeficiency syndrome	5.49e-05	0.00106	CbGeAlD
Pazopanib—CYP1A2—blood—acquired immunodeficiency syndrome	5.49e-05	0.00106	CbGeAlD
Pazopanib—CYP2C8—vagina—acquired immunodeficiency syndrome	5.43e-05	0.00105	CbGeAlD
Pazopanib—ABCG2—vagina—acquired immunodeficiency syndrome	5.28e-05	0.00102	CbGeAlD
Pazopanib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	5.21e-05	0.000614	CcSEcCtD
Pazopanib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	5.21e-05	0.000613	CcSEcCtD
Pazopanib—Flatulence—Lamivudine—acquired immunodeficiency syndrome	5.21e-05	0.000613	CcSEcCtD
Pazopanib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	5.2e-05	0.000613	CcSEcCtD
Pazopanib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	5.2e-05	0.000612	CcSEcCtD
Pazopanib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	5.18e-05	0.00061	CcSEcCtD
Pazopanib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	5.17e-05	0.000609	CcSEcCtD
Pazopanib—Pain—Zidovudine—acquired immunodeficiency syndrome	5.16e-05	0.000608	CcSEcCtD
Pazopanib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	5.16e-05	0.000608	CcSEcCtD
Pazopanib—Syncope—Ritonavir—acquired immunodeficiency syndrome	5.16e-05	0.000607	CcSEcCtD
Pazopanib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	5.15e-05	0.000607	CcSEcCtD
Pazopanib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	5.15e-05	0.000606	CcSEcCtD
Pazopanib—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	5.13e-05	0.000604	CcSEcCtD
Pazopanib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	5.12e-05	0.000603	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	5.12e-05	0.000602	CcSEcCtD
Pazopanib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	5.09e-05	0.000599	CcSEcCtD
Pazopanib—Vomiting—Didanosine—acquired immunodeficiency syndrome	5.09e-05	0.000599	CcSEcCtD
Pazopanib—Insomnia—Indinavir—acquired immunodeficiency syndrome	5.08e-05	0.000598	CcSEcCtD
Pazopanib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	5.08e-05	0.000598	CcSEcCtD
Pazopanib—Oedema—Delavirdine—acquired immunodeficiency syndrome	5.08e-05	0.000598	CcSEcCtD
Pazopanib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	5.06e-05	0.000596	CcSEcCtD
Pazopanib—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	5.06e-05	0.000595	CcSEcCtD
Pazopanib—Rash—Didanosine—acquired immunodeficiency syndrome	5.05e-05	0.000594	CcSEcCtD
Pazopanib—Infection—Delavirdine—acquired immunodeficiency syndrome	5.04e-05	0.000594	CcSEcCtD
Pazopanib—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	5.04e-05	0.000594	CcSEcCtD
Pazopanib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	5.04e-05	0.000594	CcSEcCtD
Pazopanib—Cough—Ritonavir—acquired immunodeficiency syndrome	5.02e-05	0.000591	CcSEcCtD
Pazopanib—Headache—Didanosine—acquired immunodeficiency syndrome	5.01e-05	0.00059	CcSEcCtD
Pazopanib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	5.01e-05	0.00059	CcSEcCtD
Pazopanib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	5e-05	0.000589	CcSEcCtD
Pazopanib—ABCG2—lung—acquired immunodeficiency syndrome	5e-05	0.000962	CbGeAlD
Pazopanib—Shock—Delavirdine—acquired immunodeficiency syndrome	5e-05	0.000588	CcSEcCtD
Pazopanib—Somnolence—Indinavir—acquired immunodeficiency syndrome	4.99e-05	0.000588	CcSEcCtD
Pazopanib—Asthenia—Stavudine—acquired immunodeficiency syndrome	4.99e-05	0.000587	CcSEcCtD
Pazopanib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	4.97e-05	0.000585	CcSEcCtD
Pazopanib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	4.97e-05	0.000585	CcSEcCtD
Pazopanib—Syncope—Saquinavir—acquired immunodeficiency syndrome	4.97e-05	0.000585	CcSEcCtD
Pazopanib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	4.96e-05	0.000584	CcSEcCtD
Pazopanib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	4.94e-05	0.000582	CcSEcCtD
Pazopanib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	4.94e-05	0.000581	CcSEcCtD
Pazopanib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	4.93e-05	0.000581	CcSEcCtD
Pazopanib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	4.93e-05	0.000581	CcSEcCtD
Pazopanib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	4.92e-05	0.00058	CcSEcCtD
Pazopanib—Pruritus—Stavudine—acquired immunodeficiency syndrome	4.92e-05	0.000579	CcSEcCtD
Pazopanib—Asthenia—Abacavir—acquired immunodeficiency syndrome	4.91e-05	0.000578	CcSEcCtD
Pazopanib—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	4.91e-05	0.000578	CcSEcCtD
Pazopanib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	4.9e-05	0.000577	CcSEcCtD
Pazopanib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	4.9e-05	0.000577	CcSEcCtD
Pazopanib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	4.9e-05	0.000577	CcSEcCtD
Pazopanib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	4.88e-05	0.000575	CcSEcCtD
Pazopanib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	4.88e-05	0.000575	CcSEcCtD
Pazopanib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	4.87e-05	0.000573	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	4.86e-05	0.000573	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	4.85e-05	0.000571	CcSEcCtD
Pazopanib—Pruritus—Abacavir—acquired immunodeficiency syndrome	4.84e-05	0.00057	CcSEcCtD
Pazopanib—Fatigue—Indinavir—acquired immunodeficiency syndrome	4.84e-05	0.00057	CcSEcCtD
Pazopanib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	4.84e-05	0.00057	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	4.83e-05	0.000569	CcSEcCtD
Pazopanib—Cough—Saquinavir—acquired immunodeficiency syndrome	4.83e-05	0.000569	CcSEcCtD
Pazopanib—CYP1A2—lung—acquired immunodeficiency syndrome	4.81e-05	0.000926	CbGeAlD
Pazopanib—Pain—Indinavir—acquired immunodeficiency syndrome	4.8e-05	0.000565	CcSEcCtD
Pazopanib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	4.8e-05	0.000565	CcSEcCtD
Pazopanib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	4.79e-05	0.000564	CcSEcCtD
Pazopanib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	4.78e-05	0.000563	CcSEcCtD
Pazopanib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	4.77e-05	0.000562	CcSEcCtD
Pazopanib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	4.77e-05	0.000561	CcSEcCtD
Pazopanib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	4.76e-05	0.000561	CcSEcCtD
Pazopanib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	4.75e-05	0.00056	CcSEcCtD
Pazopanib—Nausea—Didanosine—acquired immunodeficiency syndrome	4.75e-05	0.00056	CcSEcCtD
Pazopanib—Syncope—Lamivudine—acquired immunodeficiency syndrome	4.74e-05	0.000558	CcSEcCtD
Pazopanib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	4.73e-05	0.000557	CcSEcCtD
Pazopanib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	4.73e-05	0.000557	CcSEcCtD
Pazopanib—Somnolence—Efavirenz—acquired immunodeficiency syndrome	4.72e-05	0.000555	CcSEcCtD
Pazopanib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	4.71e-05	0.000555	CcSEcCtD
Pazopanib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	4.71e-05	0.000555	CcSEcCtD
Pazopanib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	4.71e-05	0.000555	CcSEcCtD
Pazopanib—Oedema—Ritonavir—acquired immunodeficiency syndrome	4.7e-05	0.000553	CcSEcCtD
Pazopanib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	4.68e-05	0.000551	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	4.68e-05	0.000551	CcSEcCtD
Pazopanib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	4.67e-05	0.00055	CcSEcCtD
Pazopanib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	4.64e-05	0.000547	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	4.63e-05	0.000545	CcSEcCtD
Pazopanib—Shock—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000544	CcSEcCtD
Pazopanib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	4.61e-05	0.000543	CcSEcCtD
Pazopanib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	4.61e-05	0.000543	CcSEcCtD
Pazopanib—Cough—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.000543	CcSEcCtD
Pazopanib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	4.61e-05	0.000543	CcSEcCtD
Pazopanib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	4.6e-05	0.000542	CcSEcCtD
Pazopanib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	4.6e-05	0.000541	CcSEcCtD
Pazopanib—Dizziness—Stavudine—acquired immunodeficiency syndrome	4.59e-05	0.000541	CcSEcCtD
Pazopanib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	4.59e-05	0.000541	CcSEcCtD
Pazopanib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	4.59e-05	0.000541	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	4.58e-05	0.000539	CcSEcCtD
Pazopanib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	4.58e-05	0.000539	CcSEcCtD
Pazopanib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	4.57e-05	0.000539	CcSEcCtD
Pazopanib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	4.56e-05	0.000537	CcSEcCtD
Pazopanib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	4.56e-05	0.000537	CcSEcCtD
Pazopanib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	4.54e-05	0.000534	CcSEcCtD
Pazopanib—Pain—Efavirenz—acquired immunodeficiency syndrome	4.54e-05	0.000534	CcSEcCtD
Pazopanib—Rash—Nevirapine—acquired immunodeficiency syndrome	4.54e-05	0.000534	CcSEcCtD
Pazopanib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	4.53e-05	0.000534	CcSEcCtD
Pazopanib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	4.53e-05	0.000533	CcSEcCtD
Pazopanib—Dizziness—Abacavir—acquired immunodeficiency syndrome	4.53e-05	0.000533	CcSEcCtD
Pazopanib—Oedema—Saquinavir—acquired immunodeficiency syndrome	4.52e-05	0.000532	CcSEcCtD
Pazopanib—Somnolence—Delavirdine—acquired immunodeficiency syndrome	4.51e-05	0.000531	CcSEcCtD
Pazopanib—Headache—Nevirapine—acquired immunodeficiency syndrome	4.51e-05	0.000531	CcSEcCtD
Pazopanib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	4.5e-05	0.00053	CcSEcCtD
Pazopanib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	4.5e-05	0.00053	CcSEcCtD
Pazopanib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	4.5e-05	0.00053	CcSEcCtD
Pazopanib—Infection—Saquinavir—acquired immunodeficiency syndrome	4.49e-05	0.000529	CcSEcCtD
Pazopanib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	4.48e-05	0.000527	CcSEcCtD
Pazopanib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	4.47e-05	0.000526	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	4.47e-05	0.000526	CcSEcCtD
Pazopanib—Shock—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000523	CcSEcCtD
Pazopanib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	4.44e-05	0.000523	CcSEcCtD
Pazopanib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	4.43e-05	0.000522	CcSEcCtD
Pazopanib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	4.43e-05	0.000522	CcSEcCtD
Pazopanib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	4.42e-05	0.000521	CcSEcCtD
Pazopanib—Vomiting—Stavudine—acquired immunodeficiency syndrome	4.42e-05	0.00052	CcSEcCtD
Pazopanib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	4.41e-05	0.00052	CcSEcCtD
Pazopanib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	4.4e-05	0.000518	CcSEcCtD
Pazopanib—Rash—Nelfinavir—acquired immunodeficiency syndrome	4.39e-05	0.000517	CcSEcCtD
Pazopanib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	4.39e-05	0.000517	CcSEcCtD
Pazopanib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	4.39e-05	0.000517	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	4.38e-05	0.000516	CcSEcCtD
Pazopanib—Rash—Stavudine—acquired immunodeficiency syndrome	4.38e-05	0.000516	CcSEcCtD
Pazopanib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.38e-05	0.000515	CcSEcCtD
Pazopanib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.38e-05	0.000515	CcSEcCtD
Pazopanib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	4.37e-05	0.000514	CcSEcCtD
Pazopanib—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.37e-05	0.000514	CcSEcCtD
Pazopanib—Headache—Stavudine—acquired immunodeficiency syndrome	4.35e-05	0.000513	CcSEcCtD
Pazopanib—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.35e-05	0.000512	CcSEcCtD
Pazopanib—Pain—Delavirdine—acquired immunodeficiency syndrome	4.34e-05	0.000511	CcSEcCtD
Pazopanib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.34e-05	0.000511	CcSEcCtD
Pazopanib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.33e-05	0.00051	CcSEcCtD
Pazopanib—Rash—Abacavir—acquired immunodeficiency syndrome	4.32e-05	0.000508	CcSEcCtD
Pazopanib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.31e-05	0.000508	CcSEcCtD
Pazopanib—Oedema—Lamivudine—acquired immunodeficiency syndrome	4.31e-05	0.000508	CcSEcCtD
Pazopanib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4.31e-05	0.000507	CcSEcCtD
Pazopanib—Headache—Abacavir—acquired immunodeficiency syndrome	4.29e-05	0.000505	CcSEcCtD
Pazopanib—Infection—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000504	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.28e-05	0.000504	CcSEcCtD
Pazopanib—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.27e-05	0.000503	CcSEcCtD
Pazopanib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.27e-05	0.000503	CcSEcCtD
Pazopanib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.25e-05	0.0005	CcSEcCtD
Pazopanib—Shock—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000499	CcSEcCtD
Pazopanib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	4.23e-05	0.000498	CcSEcCtD
Pazopanib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	4.22e-05	0.000497	CcSEcCtD
Pazopanib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	4.22e-05	0.000496	CcSEcCtD
Pazopanib—ABCB1—retina—acquired immunodeficiency syndrome	4.2e-05	0.000809	CbGeAlD
Pazopanib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	4.19e-05	0.000494	CcSEcCtD
Pazopanib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	4.19e-05	0.000493	CcSEcCtD
Pazopanib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	4.19e-05	0.000493	CcSEcCtD
Pazopanib—Somnolence—Ritonavir—acquired immunodeficiency syndrome	4.17e-05	0.000491	CcSEcCtD
Pazopanib—CYP3A4—digestive system—acquired immunodeficiency syndrome	4.17e-05	0.000802	CbGeAlD
Pazopanib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	4.17e-05	0.000491	CcSEcCtD
Pazopanib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	4.15e-05	0.000489	CcSEcCtD
Pazopanib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	4.14e-05	0.000487	CcSEcCtD
Pazopanib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	4.13e-05	0.000487	CcSEcCtD
Pazopanib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	4.13e-05	0.000487	CcSEcCtD
Pazopanib—Nausea—Stavudine—acquired immunodeficiency syndrome	4.13e-05	0.000486	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	4.12e-05	0.000485	CcSEcCtD
Pazopanib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	4.11e-05	0.000484	CcSEcCtD
Pazopanib—CYP2D6—digestive system—acquired immunodeficiency syndrome	4.1e-05	0.00079	CbGeAlD
Pazopanib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	4.09e-05	0.000481	CcSEcCtD
Pazopanib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	4.08e-05	0.000481	CcSEcCtD
Pazopanib—Nausea—Abacavir—acquired immunodeficiency syndrome	4.07e-05	0.000479	CcSEcCtD
Pazopanib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	4.06e-05	0.000478	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	4.05e-05	0.000477	CcSEcCtD
Pazopanib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	4.05e-05	0.000477	CcSEcCtD
Pazopanib—Asthenia—Indinavir—acquired immunodeficiency syndrome	4.03e-05	0.000474	CcSEcCtD
Pazopanib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	4.03e-05	0.000474	CcSEcCtD
Pazopanib—Somnolence—Saquinavir—acquired immunodeficiency syndrome	4.02e-05	0.000473	CcSEcCtD
Pazopanib—Pain—Ritonavir—acquired immunodeficiency syndrome	4.01e-05	0.000473	CcSEcCtD
Pazopanib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	4.01e-05	0.000473	CcSEcCtD
Pazopanib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	3.99e-05	0.00047	CcSEcCtD
Pazopanib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	3.98e-05	0.000468	CcSEcCtD
Pazopanib—Pruritus—Indinavir—acquired immunodeficiency syndrome	3.97e-05	0.000468	CcSEcCtD
Pazopanib—CYP3A4—blood—acquired immunodeficiency syndrome	3.97e-05	0.000765	CbGeAlD
Pazopanib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	3.93e-05	0.000463	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	3.93e-05	0.000462	CcSEcCtD
Pazopanib—CYP2D6—blood—acquired immunodeficiency syndrome	3.91e-05	0.000752	CbGeAlD
Pazopanib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	3.9e-05	0.000459	CcSEcCtD
Pazopanib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	3.9e-05	0.000459	CcSEcCtD
Pazopanib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	3.9e-05	0.000459	CcSEcCtD
Pazopanib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	3.87e-05	0.000456	CcSEcCtD
Pazopanib—Pain—Saquinavir—acquired immunodeficiency syndrome	3.86e-05	0.000455	CcSEcCtD
Pazopanib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	3.84e-05	0.000453	CcSEcCtD
Pazopanib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	3.84e-05	0.000452	CcSEcCtD
Pazopanib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	3.84e-05	0.000452	CcSEcCtD
Pazopanib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	3.84e-05	0.000452	CcSEcCtD
Pazopanib—Somnolence—Lamivudine—acquired immunodeficiency syndrome	3.83e-05	0.000451	CcSEcCtD
Pazopanib—Rash—Zidovudine—acquired immunodeficiency syndrome	3.81e-05	0.000448	CcSEcCtD
Pazopanib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	3.81e-05	0.000448	CcSEcCtD
Pazopanib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	3.8e-05	0.000448	CcSEcCtD
Pazopanib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	3.79e-05	0.000447	CcSEcCtD
Pazopanib—Headache—Zidovudine—acquired immunodeficiency syndrome	3.78e-05	0.000445	CcSEcCtD
Pazopanib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	3.75e-05	0.000442	CcSEcCtD
Pazopanib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	3.75e-05	0.000441	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	3.72e-05	0.000438	CcSEcCtD
Pazopanib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	3.72e-05	0.000438	CcSEcCtD
Pazopanib—Dizziness—Indinavir—acquired immunodeficiency syndrome	3.71e-05	0.000437	CcSEcCtD
Pazopanib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	3.71e-05	0.000437	CcSEcCtD
Pazopanib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	3.7e-05	0.000435	CcSEcCtD
Pazopanib—Pain—Lamivudine—acquired immunodeficiency syndrome	3.69e-05	0.000434	CcSEcCtD
Pazopanib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	3.64e-05	0.000429	CcSEcCtD
Pazopanib—CYP2C8—brain—acquired immunodeficiency syndrome	3.64e-05	0.0007	CbGeAlD
Pazopanib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	3.63e-05	0.000427	CcSEcCtD
Pazopanib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	3.59e-05	0.000423	CcSEcCtD
Pazopanib—Nausea—Zidovudine—acquired immunodeficiency syndrome	3.59e-05	0.000422	CcSEcCtD
Pazopanib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	3.57e-05	0.000421	CcSEcCtD
Pazopanib—Vomiting—Indinavir—acquired immunodeficiency syndrome	3.57e-05	0.00042	CcSEcCtD
Pazopanib—Rash—Indinavir—acquired immunodeficiency syndrome	3.54e-05	0.000417	CcSEcCtD
Pazopanib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	3.54e-05	0.000417	CcSEcCtD
Pazopanib—ABCG2—brain—acquired immunodeficiency syndrome	3.54e-05	0.000681	CbGeAlD
Pazopanib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	3.53e-05	0.000415	CcSEcCtD
Pazopanib—Headache—Indinavir—acquired immunodeficiency syndrome	3.52e-05	0.000414	CcSEcCtD
Pazopanib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	3.51e-05	0.000413	CcSEcCtD
Pazopanib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.47e-05	0.000409	CcSEcCtD
Pazopanib—ABCG2—lymph node—acquired immunodeficiency syndrome	3.42e-05	0.000658	CbGeAlD
Pazopanib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.41e-05	0.000401	CcSEcCtD
Pazopanib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.37e-05	0.000397	CcSEcCtD
Pazopanib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.37e-05	0.000397	CcSEcCtD
Pazopanib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.36e-05	0.000395	CcSEcCtD
Pazopanib—Rash—Efavirenz—acquired immunodeficiency syndrome	3.35e-05	0.000394	CcSEcCtD
Pazopanib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.34e-05	0.000394	CcSEcCtD
Pazopanib—Nausea—Indinavir—acquired immunodeficiency syndrome	3.34e-05	0.000393	CcSEcCtD
Pazopanib—Headache—Efavirenz—acquired immunodeficiency syndrome	3.32e-05	0.000391	CcSEcCtD
Pazopanib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.32e-05	0.000391	CcSEcCtD
Pazopanib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.24e-05	0.000382	CcSEcCtD
Pazopanib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.23e-05	0.00038	CcSEcCtD
Pazopanib—CYP3A4—nervous system—acquired immunodeficiency syndrome	3.22e-05	0.000621	CbGeAlD
Pazopanib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.21e-05	0.000378	CcSEcCtD
Pazopanib—Rash—Delavirdine—acquired immunodeficiency syndrome	3.2e-05	0.000377	CcSEcCtD
Pazopanib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.2e-05	0.000377	CcSEcCtD
Pazopanib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.2e-05	0.000376	CcSEcCtD
Pazopanib—Headache—Delavirdine—acquired immunodeficiency syndrome	3.18e-05	0.000375	CcSEcCtD
Pazopanib—CYP2D6—nervous system—acquired immunodeficiency syndrome	3.17e-05	0.000611	CbGeAlD
Pazopanib—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.15e-05	0.000371	CcSEcCtD
Pazopanib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.1e-05	0.000366	CcSEcCtD
Pazopanib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	3.1e-05	0.000598	CbGeAlD
Pazopanib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.09e-05	0.000364	CcSEcCtD
Pazopanib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.09e-05	0.000364	CcSEcCtD
Pazopanib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	3.05e-05	0.000588	CbGeAlD
Pazopanib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.05e-05	0.000359	CcSEcCtD
Pazopanib—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.02e-05	0.000355	CcSEcCtD
Pazopanib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	2.99e-05	0.000352	CcSEcCtD
Pazopanib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	2.99e-05	0.000575	CbGeAlD
Pazopanib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	2.99e-05	0.000351	CcSEcCtD
Pazopanib—Rash—Ritonavir—acquired immunodeficiency syndrome	2.96e-05	0.000349	CcSEcCtD
Pazopanib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	2.96e-05	0.000348	CcSEcCtD
Pazopanib—ABCB1—digestive system—acquired immunodeficiency syndrome	2.95e-05	0.000568	CbGeAlD
Pazopanib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	2.95e-05	0.000347	CcSEcCtD
Pazopanib—Headache—Ritonavir—acquired immunodeficiency syndrome	2.94e-05	0.000346	CcSEcCtD
Pazopanib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	2.87e-05	0.000338	CcSEcCtD
Pazopanib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	2.85e-05	0.000336	CcSEcCtD
Pazopanib—Rash—Saquinavir—acquired immunodeficiency syndrome	2.85e-05	0.000335	CcSEcCtD
Pazopanib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	2.85e-05	0.000335	CcSEcCtD
Pazopanib—Headache—Saquinavir—acquired immunodeficiency syndrome	2.83e-05	0.000333	CcSEcCtD
Pazopanib—ABCB1—blood—acquired immunodeficiency syndrome	2.81e-05	0.000541	CbGeAlD
Pazopanib—Nausea—Ritonavir—acquired immunodeficiency syndrome	2.79e-05	0.000328	CcSEcCtD
Pazopanib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	2.74e-05	0.000323	CcSEcCtD
Pazopanib—ABCB1—bone marrow—acquired immunodeficiency syndrome	2.72e-05	0.000524	CbGeAlD
Pazopanib—Rash—Lamivudine—acquired immunodeficiency syndrome	2.72e-05	0.00032	CcSEcCtD
Pazopanib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	2.72e-05	0.00032	CcSEcCtD
Pazopanib—ABCB1—spinal cord—acquired immunodeficiency syndrome	2.71e-05	0.000521	CbGeAlD
Pazopanib—Headache—Lamivudine—acquired immunodeficiency syndrome	2.7e-05	0.000318	CcSEcCtD
Pazopanib—Nausea—Saquinavir—acquired immunodeficiency syndrome	2.68e-05	0.000316	CcSEcCtD
Pazopanib—ABCB1—vagina—acquired immunodeficiency syndrome	2.61e-05	0.000502	CbGeAlD
Pazopanib—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.56e-05	0.000302	CcSEcCtD
Pazopanib—ABCB1—lung—acquired immunodeficiency syndrome	2.46e-05	0.000474	CbGeAlD
Pazopanib—CYP2D6—brain—acquired immunodeficiency syndrome	2.42e-05	0.000467	CbGeAlD
Pazopanib—ABCB1—nervous system—acquired immunodeficiency syndrome	2.28e-05	0.000439	CbGeAlD
Pazopanib—ABCB1—central nervous system—acquired immunodeficiency syndrome	2.2e-05	0.000423	CbGeAlD
Pazopanib—ABCB1—brain—acquired immunodeficiency syndrome	1.74e-05	0.000336	CbGeAlD
Pazopanib—ABCB1—lymph node—acquired immunodeficiency syndrome	1.69e-05	0.000324	CbGeAlD
Pazopanib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	8.18e-06	0.000306	CbGpPWpGaD
Pazopanib—LCK—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	8.16e-06	0.000305	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—CD4—acquired immunodeficiency syndrome	8.12e-06	0.000304	CbGpPWpGaD
Pazopanib—LCK—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	8.12e-06	0.000304	CbGpPWpGaD
Pazopanib—KIT—Immune System—CSF2—acquired immunodeficiency syndrome	8.09e-06	0.000303	CbGpPWpGaD
Pazopanib—KIT—Immune System—CD8A—acquired immunodeficiency syndrome	8.09e-06	0.000303	CbGpPWpGaD
Pazopanib—LCK—DAP12 signaling—IL6—acquired immunodeficiency syndrome	8.08e-06	0.000302	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—CD4—acquired immunodeficiency syndrome	7.98e-06	0.000299	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-B—acquired immunodeficiency syndrome	7.92e-06	0.000297	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	7.9e-06	0.000296	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.86e-06	0.000294	CbGpPWpGaD
Pazopanib—LCK—Immune System—CCR2—acquired immunodeficiency syndrome	7.86e-06	0.000294	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.85e-06	0.000294	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—TNF—acquired immunodeficiency syndrome	7.81e-06	0.000292	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	7.8e-06	0.000292	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.79e-06	0.000292	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-B—acquired immunodeficiency syndrome	7.78e-06	0.000291	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.77e-06	0.000291	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD40LG—acquired immunodeficiency syndrome	7.76e-06	0.000291	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD40LG—acquired immunodeficiency syndrome	7.74e-06	0.00029	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.74e-06	0.00029	CbGpPWpGaD
Pazopanib—FGFR2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	7.7e-06	0.000288	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CSF2—acquired immunodeficiency syndrome	7.68e-06	0.000287	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD8A—acquired immunodeficiency syndrome	7.68e-06	0.000287	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	7.66e-06	0.000287	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD8A—acquired immunodeficiency syndrome	7.66e-06	0.000287	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CSF2—acquired immunodeficiency syndrome	7.66e-06	0.000287	CbGpPWpGaD
Pazopanib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	7.6e-06	0.000284	CbGpPWpGaD
Pazopanib—LCK—DAP12 interactions—IL6—acquired immunodeficiency syndrome	7.6e-06	0.000284	CbGpPWpGaD
Pazopanib—LCK—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	7.6e-06	0.000284	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—CD4—acquired immunodeficiency syndrome	7.57e-06	0.000283	CbGpPWpGaD
Pazopanib—KIT—Signaling by NGF—IL6—acquired immunodeficiency syndrome	7.56e-06	0.000283	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.56e-06	0.000283	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—CD4—acquired immunodeficiency syndrome	7.55e-06	0.000283	CbGpPWpGaD
Pazopanib—LCK—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	7.53e-06	0.000282	CbGpPWpGaD
Pazopanib—LCK—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	7.46e-06	0.000279	CbGpPWpGaD
Pazopanib—LCK—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	7.43e-06	0.000278	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.42e-06	0.000278	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-B—acquired immunodeficiency syndrome	7.39e-06	0.000276	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-B—acquired immunodeficiency syndrome	7.37e-06	0.000276	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	7.27e-06	0.000272	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	7.25e-06	0.000271	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.18e-06	0.000269	CbGpPWpGaD
Pazopanib—FGFR1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	7.18e-06	0.000269	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling by NGF—IL6—acquired immunodeficiency syndrome	7.16e-06	0.000268	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	7.13e-06	0.000267	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IFNG—acquired immunodeficiency syndrome	7.12e-06	0.000267	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.11e-06	0.000266	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.11e-06	0.000266	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.08e-06	0.000265	CbGpPWpGaD
Pazopanib—LCK—Immune System—IFNA1—acquired immunodeficiency syndrome	7.08e-06	0.000265	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.05e-06	0.000264	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.03e-06	0.000263	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.03e-06	0.000263	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7e-06	0.000262	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.98e-06	0.000261	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.98e-06	0.000261	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD40LG—acquired immunodeficiency syndrome	6.98e-06	0.000261	CbGpPWpGaD
Pazopanib—FGFR2—Disease—CCR5—acquired immunodeficiency syndrome	6.96e-06	0.00026	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.92e-06	0.000259	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD8A—acquired immunodeficiency syndrome	6.9e-06	0.000258	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CSF2—acquired immunodeficiency syndrome	6.9e-06	0.000258	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—ALB—acquired immunodeficiency syndrome	6.88e-06	0.000258	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—CD4—acquired immunodeficiency syndrome	6.88e-06	0.000257	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD79A—acquired immunodeficiency syndrome	6.87e-06	0.000257	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.85e-06	0.000257	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.85e-06	0.000256	CbGpPWpGaD
Pazopanib—KIT—Disease—CCR5—acquired immunodeficiency syndrome	6.83e-06	0.000256	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD40LG—acquired immunodeficiency syndrome	6.83e-06	0.000256	CbGpPWpGaD
Pazopanib—LCK—Disease—CXCR4—acquired immunodeficiency syndrome	6.82e-06	0.000255	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—IL2—acquired immunodeficiency syndrome	6.81e-06	0.000255	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—CD4—acquired immunodeficiency syndrome	6.8e-06	0.000255	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD8A—acquired immunodeficiency syndrome	6.75e-06	0.000253	CbGpPWpGaD
Pazopanib—LYN—Immune System—CSF2—acquired immunodeficiency syndrome	6.75e-06	0.000253	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.75e-06	0.000252	CbGpPWpGaD
Pazopanib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	6.73e-06	0.000252	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	6.71e-06	0.000251	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	6.69e-06	0.00025	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—CD4—acquired immunodeficiency syndrome	6.66e-06	0.000249	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.66e-06	0.000249	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-B—acquired immunodeficiency syndrome	6.64e-06	0.000248	CbGpPWpGaD
Pazopanib—ITK—Immune System—IL6—acquired immunodeficiency syndrome	6.64e-06	0.000248	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.62e-06	0.000248	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.62e-06	0.000248	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.61e-06	0.000247	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.61e-06	0.000247	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.55e-06	0.000245	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.53e-06	0.000245	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	6.53e-06	0.000245	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-B—acquired immunodeficiency syndrome	6.5e-06	0.000243	CbGpPWpGaD
Pazopanib—FGFR1—Axon guidance—IL6—acquired immunodeficiency syndrome	6.5e-06	0.000243	CbGpPWpGaD
Pazopanib—FGFR1—Disease—CCR5—acquired immunodeficiency syndrome	6.48e-06	0.000243	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—CCR5—acquired immunodeficiency syndrome	6.47e-06	0.000242	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling by NGF—IL6—acquired immunodeficiency syndrome	6.45e-06	0.000241	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.44e-06	0.000241	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	6.42e-06	0.00024	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	6.4e-06	0.000239	CbGpPWpGaD
Pazopanib—FGFR3—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.39e-06	0.000239	CbGpPWpGaD
Pazopanib—FGFR3—Disease—CD4—acquired immunodeficiency syndrome	6.35e-06	0.000238	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.33e-06	0.000237	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.33e-06	0.000237	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL2—acquired immunodeficiency syndrome	6.33e-06	0.000237	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—IL6—acquired immunodeficiency syndrome	6.3e-06	0.000236	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.23e-06	0.000233	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.2e-06	0.000232	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.17e-06	0.000231	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.95e-06	0.000223	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.95e-06	0.000223	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IFNG—acquired immunodeficiency syndrome	5.92e-06	0.000222	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.89e-06	0.00022	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.83e-06	0.000218	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.83e-06	0.000218	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	5.83e-06	0.000218	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.77e-06	0.000216	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.75e-06	0.000215	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CD4—acquired immunodeficiency syndrome	5.72e-06	0.000214	CbGpPWpGaD
Pazopanib—LYN—Axon guidance—IL6—acquired immunodeficiency syndrome	5.72e-06	0.000214	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	5.69e-06	0.000213	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.62e-06	0.00021	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	5.6e-06	0.00021	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	5.58e-06	0.000209	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	5.54e-06	0.000207	CbGpPWpGaD
Pazopanib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	5.54e-06	0.000207	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	5.46e-06	0.000204	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.41e-06	0.000202	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.36e-06	0.000201	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	5.33e-06	0.000199	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.33e-06	0.000199	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.31e-06	0.000199	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.31e-06	0.000199	CbGpPWpGaD
Pazopanib—FGF1—Disease—CD4—acquired immunodeficiency syndrome	5.28e-06	0.000198	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	5.27e-06	0.000197	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL2—acquired immunodeficiency syndrome	5.26e-06	0.000197	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	5.24e-06	0.000196	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.23e-06	0.000196	CbGpPWpGaD
Pazopanib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	5.18e-06	0.000194	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	5.16e-06	0.000193	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.08e-06	0.00019	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.05e-06	0.000189	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.04e-06	0.000189	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.03e-06	0.000188	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.96e-06	0.000186	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.95e-06	0.000185	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IFNG—acquired immunodeficiency syndrome	4.9e-06	0.000183	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.87e-06	0.000182	CbGpPWpGaD
Pazopanib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	4.81e-06	0.00018	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.78e-06	0.000179	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.78e-06	0.000179	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.78e-06	0.000179	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CD4—acquired immunodeficiency syndrome	4.73e-06	0.000177	CbGpPWpGaD
Pazopanib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	4.68e-06	0.000175	CbGpPWpGaD
Pazopanib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	4.65e-06	0.000174	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	4.64e-06	0.000174	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.64e-06	0.000174	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.62e-06	0.000173	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IFNG—acquired immunodeficiency syndrome	4.57e-06	0.000171	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	4.55e-06	0.00017	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.54e-06	0.00017	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.53e-06	0.000169	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.53e-06	0.000169	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.46e-06	0.000167	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.43e-06	0.000166	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD4—acquired immunodeficiency syndrome	4.41e-06	0.000165	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	4.4e-06	0.000165	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.39e-06	0.000164	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	4.39e-06	0.000164	CbGpPWpGaD
Pazopanib—FGFR2—Disease—CD4—acquired immunodeficiency syndrome	4.37e-06	0.000163	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.37e-06	0.000163	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL2—acquired immunodeficiency syndrome	4.35e-06	0.000163	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.31e-06	0.000161	CbGpPWpGaD
Pazopanib—KIT—Disease—CD4—acquired immunodeficiency syndrome	4.29e-06	0.000161	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	4.28e-06	0.00016	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.22e-06	0.000158	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	4.1e-06	0.000154	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.09e-06	0.000153	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.09e-06	0.000153	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.08e-06	0.000153	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.08e-06	0.000153	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.08e-06	0.000153	CbGpPWpGaD
Pazopanib—FGFR1—Disease—CD4—acquired immunodeficiency syndrome	4.07e-06	0.000152	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	4.06e-06	0.000152	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL2—acquired immunodeficiency syndrome	4.06e-06	0.000152	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	4.05e-06	0.000151	CbGpPWpGaD
Pazopanib—LYN—Immune System—IFNG—acquired immunodeficiency syndrome	4.02e-06	0.00015	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.99e-06	0.000149	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	3.96e-06	0.000148	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD4—acquired immunodeficiency syndrome	3.88e-06	0.000145	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.77e-06	0.000141	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL6—acquired immunodeficiency syndrome	3.72e-06	0.000139	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.68e-06	0.000138	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	3.66e-06	0.000137	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.66e-06	0.000137	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	3.65e-06	0.000136	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.63e-06	0.000136	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.6e-06	0.000135	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.58e-06	0.000134	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL2—acquired immunodeficiency syndrome	3.57e-06	0.000134	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.56e-06	0.000133	CbGpPWpGaD
Pazopanib—FGFR3—Disease—IL6—acquired immunodeficiency syndrome	3.43e-06	0.000129	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.4e-06	0.000127	CbGpPWpGaD
Pazopanib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	3.29e-06	0.000123	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.27e-06	0.000123	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.19e-06	0.000119	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	3.18e-06	0.000119	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.15e-06	0.000118	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.12e-06	0.000117	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL6—acquired immunodeficiency syndrome	3.09e-06	0.000116	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.95e-06	0.000111	CbGpPWpGaD
Pazopanib—LCK—Disease—CD4—acquired immunodeficiency syndrome	2.94e-06	0.00011	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	2.93e-06	0.00011	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	2.92e-06	0.000109	CbGpPWpGaD
Pazopanib—FGF1—Disease—IL6—acquired immunodeficiency syndrome	2.85e-06	0.000107	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.81e-06	0.000105	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.76e-06	0.000103	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	2.7e-06	0.000101	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.62e-06	9.82e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.62e-06	9.8e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.62e-06	9.79e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL6—acquired immunodeficiency syndrome	2.56e-06	9.58e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	2.51e-06	9.4e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.41e-06	9e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—acquired immunodeficiency syndrome	2.38e-06	8.93e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	2.38e-06	8.9e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—acquired immunodeficiency syndrome	2.36e-06	8.84e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.36e-06	8.82e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—acquired immunodeficiency syndrome	2.32e-06	8.68e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.31e-06	8.64e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—acquired immunodeficiency syndrome	2.2e-06	8.24e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	2.2e-06	8.22e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.15e-06	8.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	2.14e-06	8.02e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—acquired immunodeficiency syndrome	2.1e-06	7.85e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.1e-06	7.84e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2e-06	7.48e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	1.98e-06	7.4e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.89e-06	7.08e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	1.72e-06	6.44e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	1.68e-06	6.28e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.65e-06	6.19e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.62e-06	6.08e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—acquired immunodeficiency syndrome	1.59e-06	5.94e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.54e-06	5.77e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.54e-06	5.76e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.46e-06	5.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.39e-06	5.19e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.38e-06	5.15e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.36e-06	5.08e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.17e-06	4.37e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.11e-06	4.16e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	9e-07	3.37e-05	CbGpPWpGaD
